The FDA is facing significant turmoil following the resignation of George Tidmarsh, the top drug regulator, amid serious concerns about his personal conduct. Tidmarsh’s departure comes in light of an inquiry by federal officials and a lawsuit initiated by a drug company, raising questions about ethics within the agency. Allegations of a toxic work environment and misconduct have surfaced, further complicating the situation. Despite stepping down, Tidmarsh has expressed intentions to contest the circumstances of his exit. This turmoil not only highlights internal challenges at the FDA but also impacts ongoing relations with the pharmaceutical industry, particularly with brands like Aurinia, which have voiced grievances regarding the regulatory process.